These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 12740001)
1. Safety and efficacy of tenecteplase in acute myocardial infarction. Guerra DR; Karha J; Gibson CM Expert Opin Pharmacother; 2003 May; 4(5):791-8. PubMed ID: 12740001 [TBL] [Abstract][Full Text] [Related]
2. Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction. Dunn CJ; Goa KL Am J Cardiovasc Drugs; 2001; 1(1):51-66. PubMed ID: 14728052 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Tanswell P; Modi N; Combs D; Danays T Clin Pharmacokinet; 2002; 41(15):1229-45. PubMed ID: 12452736 [TBL] [Abstract][Full Text] [Related]
4. Issues in the assessment of the safety and efficacy of tenecteplase (TNK-tPA). Gibson CM; Marble SJ Clin Cardiol; 2001 Sep; 24(9):577-84. PubMed ID: 11558838 [TBL] [Abstract][Full Text] [Related]
6. Tenecteplase for treatment of acute myocardial infarction. Turcasso NM; Nappi JM Ann Pharmacother; 2001 Oct; 35(10):1233-40. PubMed ID: 11675853 [TBL] [Abstract][Full Text] [Related]
7. Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction. Melandri G; Vagnarelli F; Calabrese D; Semprini F; Nanni S; Branzi A Vasc Health Risk Manag; 2009; 5(1):249-56. PubMed ID: 19436656 [TBL] [Abstract][Full Text] [Related]
8. A review of available fibrin-specific thrombolytic agents used in acute myocardial infarction. Tsikouris JP; Tsikouris AP Pharmacotherapy; 2001 Feb; 21(2):207-17. PubMed ID: 11213858 [TBL] [Abstract][Full Text] [Related]
10. "Tenecteplase--the best among the equals.". Saran RK; Sethi R; Nagori M Indian Heart J; 2009; 61(5):454-8. PubMed ID: 20635761 [TBL] [Abstract][Full Text] [Related]
11. Alteplase and tenecteplase: applications in the peripheral circulation. Semba CP; Sugimoto K; Razavi MK; Tech Vasc Interv Radiol; 2001 Jun; 4(2):99-106. PubMed ID: 11981795 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of tenecteplase: results from a phase II study in patients with acute myocardial infarction. Modi NB; Fox NL; Clow FW; Tanswell P; Cannon CP; Van de Werf F; Braunwald E J Clin Pharmacol; 2000 May; 40(5):508-15. PubMed ID: 10806604 [TBL] [Abstract][Full Text] [Related]
13. Tenecteplase for the treatment of acute ischemic stroke: A review of completed and ongoing randomized controlled trials. Coutts SB; Berge E; Campbell BC; Muir KW; Parsons MW Int J Stroke; 2018 Dec; 13(9):885-892. PubMed ID: 30035698 [TBL] [Abstract][Full Text] [Related]
14. Tenecteplase: new preparation. Another thrombolytic agent for myocardial infarction: a slightly simpler treatment. Prescrire Int; 2002 Jun; 11(59):83-4. PubMed ID: 12068843 [TBL] [Abstract][Full Text] [Related]
15. Comparison of pharmacokinetic properties of alteplase and tenecteplase. The future of thrombolysis in acute ischemic stroke. Marè A; Lorenzut S; Janes F; Gentile C; Marinig R; Tereshko Y; Gigli GL; Valente M; Merlino G Expert Opin Drug Metab Toxicol; 2024; 20(1-2):25-36. PubMed ID: 38275111 [TBL] [Abstract][Full Text] [Related]
16. Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase. Szabo S; Letsch R; Ehlers R; Walter T; Kazmaier S; Helber U; Hoffmeister HM Thromb Res; 2002 Apr; 106(2):113-9. PubMed ID: 12182909 [TBL] [Abstract][Full Text] [Related]